134 related articles for article (PubMed ID: 27434288)
21. Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma.
Wu W; Miao L; Zhao L; Zhu Y; Mao J; Cai Z; Ji Y; Wang L; Wang Y; Jia T
Hematology; 2024 Dec; 29(1):2293514. PubMed ID: 38108323
[TBL] [Abstract][Full Text] [Related]
22. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
23. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma.
Morito T; Fujihara M; Asaoku H; Tari A; Sato Y; Ichimura K; Tanaka T; Takata K; Tamura M; Yoshino T
Cancer Sci; 2009 Jul; 100(7):1255-60. PubMed ID: 19432905
[TBL] [Abstract][Full Text] [Related]
25. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
26. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
27. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
Wang C; Li W; Liu C; He H; Bai O
Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
[TBL] [Abstract][Full Text] [Related]
28. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
[TBL] [Abstract][Full Text] [Related]
30. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
31. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
[TBL] [Abstract][Full Text] [Related]
32. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy.
Riihijärvi S; Nurmi H; Holte H; Björkholm M; Fluge O; Pedersen LM; Rydström K; Jerkeman M; Eriksson M; Leppä S
Eur J Haematol; 2012 Nov; 89(5):395-402. PubMed ID: 22882209
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
34. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.
Sugita Y; Ohwada C; Kawaguchi T; Muto T; Tsukamoto S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Shimizu N; Tanaka H; Abe D; Fukazawa M; Sugawara T; Aotsuka N; Nishiwaki K; Shono K; Ebinuma H; Fujimura K; Bujo H; Yokote K; Nakaseko C
Clin Chim Acta; 2016 Dec; 463():47-52. PubMed ID: 27725222
[TBL] [Abstract][Full Text] [Related]
36. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
38. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N; Tsurumi H; Kasahara S; Kanemura N; Hara T; Yasuda I; Shimizu M; Murakami N; Sawada M; Yamada T; Takemura M; Seishima M; Kito Y; Takami T; Moriwaki H
Eur J Haematol; 2011 Sep; 87(3):217-27. PubMed ID: 21575062
[TBL] [Abstract][Full Text] [Related]
39. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
Chihara D; Oki Y; Ine S; Kato H; Onoda H; Taji H; Kagami Y; Yamamoto K; Morishima Y
Eur J Haematol; 2010 Jun; 84(6):493-8. PubMed ID: 20148943
[TBL] [Abstract][Full Text] [Related]
40. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]